Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Frequently asked questions
What sector does Mind Medicine Inc (MMED) operate in?
Mind Medicine Inc belongs to the Healthcare sector and operates in the industry.
What is Mind Medicine Inc (MMED) current stock price?
As of the latest data, Mind Medicine Inc stock price is CA$0.00, with a previous close of CA$0.00.
What is Mind Medicine Inc (MMED) Earnings Per Share (EPS)?
The trailing EPS is -CA$3.31, and the forward EPS is -CA$0.27.
Does Mind Medicine Inc (MMED) pay dividends?
No. Mind Medicine Inc does not pay a dividend.
What is Mind Medicine Inc (MMED) beta (volatility) score?
Mind Medicine Inc has a beta of 2.482, indicating very high volatility compared to the market.